Actinogen Medical down 9.3pc despite tax rebate
  • Biotech company Actinogen Medical has pocketed $4.58 million today from research and development tax incentives
  • Most recently, the company completed trials of its lead drug Xanamem — aimed at treating Alzheimer's
  • Results released at the beginning of this month showed the drug positively affected cognitive abilities in patients over a 12 week period
  • At the time, shares in the company rocketed over 466 per cent after the announcement hit punter's eyes
  • However today, the company's shares opened at 4.4 cents and dropped 9.3 per cent to trade at 3.9 cents each.

Actinogen Medical dropped 9.3 per cent on the market today, despite announcing a multi-million dollar tax rebate.

The company received the $4.58 million research and development tax rebate as part of an incentive initiative for work carried out during the 2018/19 financial year.

"While the company is fully funded for its existing and ongoing studies, the tax rebate helps bolster our financial position," Actinogen CEO Dr Bill Ketelbey said.

The company commented in a media release today it also expects an additional $650,000 in further rebates this year.

The tax refund comes as well-timed for the company as it prepares to optimise clinical development of its leading candidate drug, Xanamem.

Xanamem is a drug being developed in response to evidence that there's an association between the progression of Alzheimer's disease and raised cortisol levels in the blood.

At the beginning of this month, the company saw breakthrough results of the drug during its 'XanaHES' study. Daily doses of the drug over 12 weeks showed positive cognitive results on elderly test patients.

"Our focus in the months ahead is on completing the ongoing Xanamem studies, and determining how best these results, along with the breakthrough XanaHES results announced previously, best shape Xanamem’s future clinical development program," Dr Bill added.

The positive results exhibited from Xanamem at the start of this month caused a massive 466 per cent spike to the company's share price.

However, today's announcement wasn't enough to continue a trend of massive growth.

Today, the company's shares opened at 4.4 cents and dropped 9.3 per cent to trade at 3.9 cents each.

"We look forward to updating the market and shareholders on this progress in the near future," Dr Bill concluded today.


ACW by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Founder, Managing Director & CEO, John Kelly - The Market Herald

" Atomo Diagnostics (ASX:AT1) receives TGA approval for COVID-19 test

Atomo Diagnostics (AT1) has received the tick of approval from the Australian Therapeutic Goods Administration (TGA) for its COVID-19 rapid antibody test.
Medibio (ASX:MEB) - Managing Director, Claude Solitario - The Market Herald

" Medibio (ASX:MEB) granted U.S. patent for stress monitor

Mental health tech company Medibio (MEB) has been granted a patent by the U.S. Patent and Trademark Office.
Getting enough sleep? Mental wellness app spikes 117 per cent with new signing

" Medibio’s (ASX:MEB) sleep software and study affected by COVID-19

Meditech company Medibio (MEB) has revealed it’s facing some setbacks due to the ongoing coronavirus pandemic.
Kazia Therapeutics (ASX:KZA) - CEO & Executive Director, Dr James Garner - The Market Herald

" Kazia Therapeutics’ (ASX:KZA) paxalisib obtains rare paediatric disease designation

Kazia Therapeutics (KZA) has obtained rare paediatric disease designation (RPDD) for paxalisib in treating a form of childhood brain cancer.